CLARITY PHARMACEUTICALS LIMITED (CU6)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CU6 - CLARITY PHARMACEUTICALS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: N/A
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.49

05 Dec
2023

0.010

OPEN

$1.50

0.68%

HIGH

$1.50

199,706

LOW

$1.47

TARGET
$1.70 14.1% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CYC . EBR . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
CU6: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 9.5 - 12.8 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 20192020202120222023
EPS Basic xxxxxxxxxxxx-9.5
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx-
Book Value Per Share xxxxxxxxxxxx26.5
Net Operating Cash Flow xxxxxxxxxxxx-27.5 M
Net Profit Margin xxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20192020202120222023
Return on Capital Employed xxxxxxxxxxxx-30.48 %
Return on Invested Capital xxxxxxxxxxxx-30.48 %
Return on Assets xxxxxxxxxxxx-27.84 %
Return on Equity xxxxxxxxxxxx-30.48 %
Return on Total Capital xxxxxxxxxxxx-44.81 %
Free Cash Flow ex dividends xxxxxxxxxxxx-27.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20192020202120222023
Short-Term Debt xxxxxxxxxxxx-
Long Term Debt xxxxxxxxxxxx-
Total Debt xxxxxxxxxxxx-
Goodwill - Gross xxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxx65 M
Price To Book Value xxxxxxxxxxxx2.64

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20192020202120222023
Capex xxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx36 M
Research & Development xxxxxxxxxxxx31 M
Investments - Total xxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

15/09/2023

1

Speculative Buy

$1.70

14.09%

Clarity Pharmaceuticals is targeting the imaging and treatment of metastatic prostate cancer. The patient group is the subject of three ongoing clinical trials with preliminary results showing that 30% were positive in relation to the company's therapeutics.

While early days, Bell Potter notes the results appear highly encouraging. Speculative Buy retained. Target rises to $1.70 from $1.30.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -12.80 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -8.90 cents.
Access Stockbroker Research History >

CU6 STOCK CHART

FNArena News on CU6

1
Australian Broker Call *Extra* Edition – Sep 06, 2023

Sep 06 2023 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Aug 11, 2023

Aug 11 2023 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Jul 06, 2023

Jul 06 2023 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Jun 30, 2023

Jun 30 2023 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – May 30, 2023

May 30 2023 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Dr Boreham’s Crucible: Pro Medicus

Oct 23 2023 - Australia
2
Dr Boreham’s Crucible: Cyclopharm

Oct 09 2023 - Small Caps
3
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps
4
Margins Signal Integral Diagnostics Recovery

Sep 07 2023 - Australia
5
ResMed: Finding A Base?

Aug 15 2023 - Technicals
6
August Turns ResMed Into Nigel NoMates

Aug 09 2023 - Australia
7
Dr Boreham’s Crucible: Lumos Diagnostics

Jun 19 2023 - Small Caps
8
Fisher & Paykel Healthcare: Lower Margin, Higher Spending

May 30 2023 - Australia
9
Dr Boreham’s Crucible: Impedimed

May 08 2023 - Small Caps
10
Treasure Chest: ResMed’s Benevolent Monopoly

May 01 2023 - Treasure Chest